Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab) led to a significant reduction in disability progression…
Elan and Biogen Suspend Marketeing of TYSABRI
Elan and Biogen Idec’s ongoing safety evaluation of TYSABRI has led to a previously diagnosed case of malignant astrocytoma being reassessed as progressive multifocal leukoencephalopathy (PML).